Literature DB >> 23796932

Evaluation of Combinations of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Clinically Used Antiretroviral Drugs.

Atsuko Hachiya1,2, Aaron B Reeve3, Bruno Marchand1, Eleftherios Michailidis1, Yee Tsuey Ong1, Karen A Kirby1, Maxwell D Leslie1, Shinichi Oka2, Eiichi N Kodama4, Lisa C Rohan5,6, Hiroaki Mitsuya7,8, Michael A Parniak3, Stefan G Sarafianos9,10.   

Abstract

Drug combination studies of 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) with FDA-approved drugs were evaluated by two different methods, MacSynergy II and CalcuSyn. Most of the combinations, including the combination of the two adenosine analogs EFdA and tenofovir, were essentially additive, without substantial antagonism or synergism. The combination of EFdA and rilpivirine showed apparent synergism. These studies provide information that may be useful for the design of EFdA combination regimens for initial and salvage therapy assessment.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.

Entities:  

Year:  2013        PMID： 23796932      PMCID： PMC3754316          DOI： 10.1128/AAC.00283-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  32 in total

1.  FDA approves two combination pills, Epzicom and Truvada; comment on commercial race to once-a-day nucleosides.

Authors:  John S James
Journal:  AIDS Treat News       Date:  2004-07-23

Review 2.  A three-dimensional model to analyze drug-drug interactions.

Authors:  M N Prichard; C Shipman
Journal:  Antiviral Res       Date:  1990 Oct-Nov       Impact factor: 5.970

3.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

4.  In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase.

Authors:  Urvi M Parikh; Dianna L Koontz; Chung K Chu; Raymond F Schinazi; John W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

5.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

6.  Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3'-azido-3'-deoxythymidine with nonnucleoside inhibitors.

Authors:  Carlos Cruchaga; Leticia Odriozola; Marieline Andréola; Laura Tarrago-Litvak; Juan J Martínez-Irujo
Journal:  Biochemistry       Date:  2005-03-08       Impact factor: 3.162

7.  Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.

Authors:  Eleftherios Michailidis; Bruno Marchand; Eiichi N Kodama; Kamlendra Singh; Masao Matsuoka; Karen A Kirby; Emily M Ryan; Ali M Sawani; Eva Nagy; Noriyuki Ashida; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

Review 8.  The first once-daily single-tablet regimen for the treatment of HIV-infected patients.

Authors:  Ben Killingley; Anton Pozniak
Journal:  Drugs Today (Barc)       Date:  2007-07       Impact factor: 2.245

9.  The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.

Authors:  G Borkow; D Arion; M A Wainberg; M A Parniak
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

10.  Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L- and D-nucleosides.

Authors:  Elisabetta Sabini; Saugata Hazra; Manfred Konrad; Arnon Lavie
Journal:  J Med Chem       Date:  2007-05-27       Impact factor: 7.446
View more
  12 in total

1.  Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.

Authors:  Atsuko Hachiya; Karen A Kirby; Yoko Ido; Urara Shigemi; Masakazu Matsuda; Reiko Okazaki; Junji Imamura; Stefan G Sarafianos; Yoshiyuki Yokomaku; Yasumasa Iwatani
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

2.  Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA).

Authors:  Zhe Li Salie; Karen A Kirby; Eleftherios Michailidis; Bruno Marchand; Kamalendra Singh; Lisa C Rohan; Eiichi N Kodama; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-03       Impact factor: 11.205

3.  SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors.

Authors:  Andrew D Huber; Eleftherios Michailidis; Megan L Schultz; Yee T Ong; Nicolin Bloch; Maritza N Puray-Chavez; Maxwell D Leslie; Juan Ji; Anthony D Lucas; Karen A Kirby; Nathaniel R Landau; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

4.  Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes.

Authors:  Duncan T Njenda; Shambhu G Aralaguppe; Kamalendra Singh; Rohit Rao; Anders Sönnerborg; Stefan G Sarafianos; Ujjwal Neogi
Journal:  J Antimicrob Chemother       Date:  2018-10-01       Impact factor: 5.790

5.  Vaginal Microbicide Film Combinations of Two Reverse Transcriptase Inhibitors, EFdA and CSIC, for the Prevention of HIV-1 Sexual Transmission.

Authors:  Wei Zhang; Minlu Hu; Yuan Shi; Tiantian Gong; Charlene S Dezzutti; Bernard Moncla; Stefan G Sarafianos; Michael A Parniak; Lisa C Rohan
Journal:  Pharm Res       Date:  2015-03-21       Impact factor: 4.200

6.  Specific mutations in the HIV-1 G-tract of the 3'-polypurine tract cause resistance to integrase strand transfer inhibitors.

Authors:  Atsuko Hachiya; Mai Kubota; Urara Shigemi; Hirotaka Ode; Yoshiyuki Yokomaku; Karen A Kirby; Stefan G Sarafianos; Yasumasa Iwatani
Journal:  J Antimicrob Chemother       Date:  2022-02-23       Impact factor: 5.790

Review 7.  4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor.

Authors:  Martin Markowitz; Stefan G Sarafianos
Journal:  Curr Opin HIV AIDS       Date:  2018-07       Impact factor: 4.283

8.  4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms.

Authors:  Eleftherios Michailidis; Andrew D Huber; Emily M Ryan; Yee T Ong; Maxwell D Leslie; Kayla B Matzek; Kamalendra Singh; Bruno Marchand; Ariel N Hagedorn; Karen A Kirby; Lisa C Rohan; Eiichi N Kodama; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2014-06-26       Impact factor: 5.157

Review 9.  Avoiding Drug Resistance in HIV Reverse Transcriptase.

Authors:  Maria E Cilento; Karen A Kirby; Stefan G Sarafianos
Journal:  Chem Rev       Date:  2021-01-28       Impact factor: 60.622

Review 10.  Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase.

Authors:  Kamal Singh; Stefan G Sarafianos; Anders Sönnerborg
Journal:  Pharmaceuticals (Basel)       Date:  2019-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.